# US 2012/0253264 A1 · Photochemical internalization method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253264 A1
- Document ID: US20120253264A1
- Status: Published application
- Kind: A1
- Application number: 13/390,360
- Filed: 2010-08-16
- Published: 2012-10-04
- Earliest claimed: 2009-08-14
- Inventors: Jo Klaveness; Anders Hogset
- Web page: https://patentgrep.com/patent/US20120253264A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods of introducing drugs into cells which are located in body cavities. In particular, it provides a photosensitizing agent for use in a method of introducing a drug molecule into the cytosol of a cell located within a body cavity, said method comprising the step of contacting said cell with said photosensitizing agent and said drug molecule, and irradiating the cell with light of a wavelength effective to activate the photosensitizing agent. Such methods are particularly suitable for use in the delivery of cytotoxic drugs in the treatment of cancer, especially bladder cancer, ovarian cancer, cervical cancer, lung cancer, brain cancer, colorectal cancer and cancers of the oral and nasal cavity.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of introducing a drug molecule into the cytosol of a cell located within a body cavity, the method comprising
contacting said cell with a photosensitizing agent and said drug molecule, and
irradiating the cell with light of a wavelength effective to activate the photosensitizing agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein said body cavity is a urinary bladder, an oral cavity, a nasal cavity, a female reproductive body cavity system, an abdominal cavity (peritoneum), a lower part of the gastrointestinal system, a cranial cavity, an eye (intravitreous), a lung and bronchial system, or a cavity generated after surgery.

### Claim 23 (depends on 22)

The method of claim 22, wherein said body cavity is a urethra, a vaginal cavity, a rectum and/or a colon, or a cavity generated following tumor surgery.

### Claim 24 (depends on 21)

The method of claim 21, wherein said photosensitizing agent is selected from a phthalocyanine; a sulphonated tetraphenylporphyrin; nile blue; a chlorin; uroporphyrin I; phylloerythrin; a porpyhrin; methylene blue; a cationic dye; a tetracycline; a naphthalocyanine; a texaphyrine; a pheophorbide; a purpurin; a rhodamine; a fluorescein; a lysosomotropic weak base; and a porphycene.

### Claim 25 (depends on 24)

The method of claim 24, wherein said photosensitizing agent is selected from AlPcS2, AlPcS2a, TPPS2a, TPPS4, TPPS1, TPPS2o, a bacteriochlorin, a ketochlorin, a hematoporphyrin, and a benzoporphyrin.

### Claim 26 (depends on 24)

The method of claim 24, wherein said photosensitizing agent is selected from TPCS2a, TPPS2a, AlPcS2a, TPPS4, and porfimer.

### Claim 27 (depends on 21)

The method of claim 21, wherein said photosensitizing agent is provided in the form of a pharmaceutically acceptable salt having a water solubility of at least 0.5 mg/ml.

### Claim 28 (depends on 27)

The method of claim 27, wherein said salt is formed from a pharmaceutically acceptable base.

### Claim 29 (depends on 28)

The method of claim 28, wherein said pharmaceutically acceptable base is an organic amine.

### Claim 30 (depends on 29)

The method of claim 29, wherein said organic amine is an amino alcohol.

### Claim 31 (depends on 30)

The method of claim 30, wherein said amino alcohol is a lower aliphatic amino alcohol; a cyclic amino alcohol; or an amino sugar.

### Claim 32 (depends on 30)

The method of claim 30, wherein said amino alcohol is selected from monoethanolamine, di-ethanolamine, tri-ethanolamine, 2-amino-2-(hydroxymethyl)propane-1,3-diol, 4-(2-hydroxyethyl)-morpholine, 1-(2-hydroxyethyl)-pyrrolidine, glucamine, and N-methylglucamine (meglumine).

### Claim 33 (depends on 27)

The method of claim 27, wherein said salt is formed from a pharmaceutically acceptable acid.

### Claim 34 (depends on 33)

The method of claim 33, wherein said pharmaceutically acceptable acid is a sulphonic acid.

### Claim 35 (depends on 21)

The method of claim 21, wherein said drug molecule is selected from the group consisting of anti-cancer drugs, antibacterial substances, anti-virals, anti-fungal agents, immune-modulating drugs, anti-inflammatories, analgesics, gene therapy agents, oligonucleotides, and gene expression modifying agents.

### Claim 36 (depends on 35)

The method of claim 35, wherein said drug molecule is bleomycin.

### Claim 37 (depends on 21)

The method of claim 21, wherein the photosensitizing agent and the drug molecule are contacted simultaneously, separately or sequentially.

### Claim 38 (depends on 35)

The method of claim 35, wherein said anti-cancer drug comprises a biomolecule prepared by recombinant technology.

### Claim 39 (depends on 35)

The method of claim 35, wherein said anti-cancer drug specifically targets gene products over-expressed in target cells, a cellular protein-based target or a cellular non-protein-based target, or which targets an enzyme.

### Claim 40 (depends on 35)

The method of claim 35, wherein said immune-modulating drug is selected from protein or peptide antigens for vaccine or immune-stimulating purposes, immune-stimulating oligonucleotides, genes encoding antigens or immune-modulating proteins or peptides, oligonucleotides modifying gene expression in the immune response system, and small molecule drugs having immune-modulating properties.

### Claim 41 (depends on 21)

The method of claim 21, wherein said photosensitizing agent and said drug molecule are present in a single pharmaceutical composition.

### Claim 42 (depends on 21)

The method of claim 21 which is a method of treating cancer or a method of gene or oligonucleotide therapy.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer is selected from bladder cancer, ovarian cancer, cervical cancer, lung cancer, brain cancer, colorectal cancer, and cancers of the oral or nasal cavity.

### Claim 44 (depends on 21)

The method of claim 21 which is a method of treating infections.

### Claim 45 (depends on 44)

The method of claim 44, wherein the infection is caused by a virus, by bacteria, or by fungi.
